Empagliflozin

CHICAGO — A meta-analysis of 13 large SGLT2 inhibitor trials, including the recently published EMPA-KIDNEY trial, indicates that the drug class reduces CV and renal outcomes across all high-risk groups, with and without type 2 diabetes.

ORLANDO —Empagliflozin reduced kidney disease progression and cardiovascular death in patients with chronic kidney disease, according to data presented at ASN Kidney Week.

In adults with HF, empagliflozin was associated with a reduction in new macroalbuminuria in patients with macroalbuminuria at baseline compared with placebo.

Approximately 52% of patients with HF are categorized as those with a preserved ejection fraction. Hospitalizations in this patient population are continuing to increase.

ATLANTA — Use of empagliflozin was associated with a nearly 40% reduced risk for nephrolithiasis among people with type 2 diabetes, according to data presented at ENDO 2022.

The American Diabetes Association announced updates to its 2022 Standards of Medical Care in Diabetes to reflect new data on cardiovascular outcomes with diabetes and kidney disease and use of SGLT2 inhibitors.

WASHINGTON — Patients with acute HF assigned the SGLT2 inhibitor empagliflozin saw a greater improvement in HF symptoms, physical limitations and quality of life measures vs. placebo, with benefit seen as early as 15 days, data show.

Empagliflozin added to automated insulin delivery or predictive low-glucose suspend systems significantly benefited daytime glucose levels for people with type 1 diabetes, with no extra hypoglycemia risk, according to new data.

The benefit of the SGLT2 inhibitor empagliflozin in patients with HF with preserved ejection fraction did not differ between those who did or did not receive mineralocorticoid receptor antagonists, researchers reported.

The EMPA-Kidney trial will stop early due to evidence of Jardiance’s positive efficacy among patients with chronic kidney disease, according to a press release.